Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2023
Product Development Highlights:
Selected neuroplastogen lead candidate EB-003, a potential first-in-class therapeutic option for addressing difficult-to-treat mental health disorders by promoting neuroplasticity without inducing hallucinations.
Started IND-enabling preclinical activities for EB-002 and completed important repeat-dose toxicology studies, genotoxicity studies, and key cardiac, respiratory, and CNS safety pharmacology studies.
Corporate and Business Development Highlights:
Signed three non-binding term sheets with an undisclosed biotechnology company to pursue the out-licensing of three classes of compounds from the Company's extensive portfolio of assets.
Signe
